Human CD17 / Lactosylceramide

Mouse

Human (tested or 100% immunogen sequence identity)

IgM Monoclonal

HO18.3G-6.F5

Unconjugated

PEG purified

Unmodified. Also available Azide-free, BSA-free.

Beta-2 Microglobulin associated proteins from a detergent lysate of human PBLs were used as the immunogen for the CDw17 antibody.

Human CD17 / Lactosylceramide

• Immunofluorescence (0.5 - 1 µg/ml)
• Flow Cytometry (0.5 - 1 µg/10E6 cells)

CD17 is an intermediate glycosphingolipid from the metabolism of higher gangliosides that localizes to sphingolipid-sterol rafts. CD17 is detectable in monocytes, granulocytes, basophils, platelets, a subset of peripheral B cells (CD19+) and tonsil dendritic cells. It is rapidly down regulated on activated granulocytes and is upregulated on IL-2 activated T lymphocytes. CD17 binds to bacteria and may function in phagocytosis. VEGF-treated endothelial cells can produce CD17, which can then mediate signaling toward PECAM-1 expression and angiogenesis. TNFa-induced astrogliosis (astrocyte proliferation and glial fibrillary acidic protein (GFAP) upregulation) in response to neuro-inflammation (i.e. spinal cord injury) causes an increase in intracellular levels of CD17. Aberrant levels of glycosphingolipids are a feature of cancer cells and may influence integrin clustering and internalization. Optimal dilution of the CDw17 antibody should be determined by the researcher.

1X PBS, 0.1 mg/ml BSA, 0.05% sodium azide

Store at 2°C to 8°C.

For research use only. Intended for use by laboratory professionals.

This antibody carries the LSBio 100% Guarantee.